Imugene’s PD1-Vaxx is a B-cell cancer immunotherapy designed to treat tumors such as lung cancer by interfering with PD-1/PD-L1 binding and interaction, and produce an anti-cancer effect similar to Keytruda, Opdivo, and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.
Above is excerpt from todays announcement.
Imagine our little company being in the same sphere as Keytruda?
We're massively undervalued IMO.
Ann: Imugene Receives Third PD1-VAXX Ethics Trial Approval, page-13
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.010(3.57%) |
Mkt cap ! $77.89M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.3¢ | $1.990M | 7.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 209631 | 9 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |